Tandem Diabetes Care

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.







Nach einem unsäglichen Absturz hat sich der Wert in den vergangenen 12 Monaten verzwanzigfacht.
Diabetes ist vermutlich bis auf Weiteres ein brummender Markt.

Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates

Tandem Diabetes Care, Inc. (TNDM - Free Report) reported earnings per share of 2 cents in fourth-quarter 2018 compared with net loss of $1.23 posted in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 22 cents.

For the full year, the company registered loss of $2.55 per share, much narrower than the year-ago loss of $12.87 per share. The Zacks Consensus Estimate was pegged at a loss of $3.22 per share.

Revenues in Detail

Revenues in the quarter totaled $76.2 million, sailing past the Zacks Consensus Estimate by 34.9%. The top line also surged 89.1% from the year-ago quarter.

The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, strengthening the company’s core business, along with its international launch, considerably drove top-line growth.

In the fourth quarter, Tandem Diabetes’ pump shipments soared 133% year over year to 16,168 pumps.Of these, 3,200 pumps were shipped to international markets. Accordingly, Tandem Diabetes recorded international sales of $7.1 million in the quarter.

...

https://www.zacks.com/stock/news/357149/...-estimates